Pfizer Ceases Production of Dual-Dose Weight Loss Medication Following Elevated Incidence of Adverse Effects

Pfizer Ceases Production of Dual-Dose Weight Loss Medication Following Elevated Incidence of Adverse Effects

On Friday, Pfizer announced the discontinuation of the development of the twice-daily variant of its experimental weight loss pill. This decision follows a mid-stage clinical study where obese patients experienced substantial weight loss while facing challenges in tolerating the drug. The pharmaceutical company noted elevated rates of adverse side effects, ...

Read More »